Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Capital Expenditures (2016 - 2025)

Perspective Therapeutics (CATX) has disclosed Capital Expenditures for 16 consecutive years, with -$7.5 million as the latest value for Q4 2025.

  • Quarterly Capital Expenditures fell 15806.25% to -$7.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $135000.0 through Dec 2025, up 87.5% year-over-year, with the annual reading at $135000.0 for FY2025, 87.5% up from the prior year.
  • Capital Expenditures hit -$7.5 million in Q4 2025 for Perspective Therapeutics, down from $7.6 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $10.1 million in Q2 2024 to a low of -$10.1 million in Q3 2024.
  • Historically, Capital Expenditures has averaged $102235.3 across 5 years, with a median of $90000.0 in 2022.
  • Biggest five-year swings in Capital Expenditures: soared 5612.02% in 2024 and later crashed 15806.25% in 2025.
  • Year by year, Capital Expenditures stood at -$86000.0 in 2021, then soared by 275.58% to $151000.0 in 2022, then skyrocketed by 598.01% to $1.1 million in 2023, then plummeted by 95.45% to $48000.0 in 2024, then plummeted by 15806.25% to -$7.5 million in 2025.
  • Business Quant data shows Capital Expenditures for CATX at -$7.5 million in Q4 2025, $7.6 million in Q3 2025, and -$4.6 million in Q2 2025.